The Lancet, 397(10278), 971984
And it's not a full guarantee that everyone who wants to use these GLP-1s for cheap can do so using Medicare
Aim for 0.7 to 1.0 grams per pound of body weight daily
Beginning July 1, 2026, the Medicare GLP-1 Bridge Program may allow eligible Medicare Part D patients to access certain obesity-indicated GLP-1 medications, including Foundayo, Wegovy, and certain Zepbound formulations, for no more than $50 per month through December 31, 2027
Like semaglutide, it was first approved to help manage type 2 diabetes and then approved for weight loss
They work in the gut like the bodys natural GLP-1, slowing digestion, curbing hunger, and signaling fullness to the brain